BC
APLS

Brookfield Corp’s Apellis Pharmaceuticals APLS Stock Holding History

Brookfield Corp’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-61,414
Closed -$5.59M – 138
2023
Q2 		$5.59M Sell
61,414
-54,726
-47% -$4.72M 0.02% 251
2023
Q1 		$7.66M Buy
116,140
+49,914
+75% +$2.88M 0.03% 220
2022
Q4 		$3.42M Buy
66,226
+5,996
+10% +$318K 0.01% 327
2022
Q3 		$4.11M Buy
60,230
+25,890
+75% +$1.53M 0.02% 301
2022
Q2 		$1.55M Buy
34,340
+19,474
+131% +$888K 0.01% 452
2022
Q1 		$755K Buy
+14,866
New +$656K ﹤0.01% 526

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Brookfield Corp's APLS Position: Q3 2023 in Review

Brookfield Corp sold out of Apellis Pharmaceuticals (APLS) in Q3 2023, closing a stake of 61,414 shares — an estimated $5.59M sold.

Brookfield Corp first reported a position in APLS in Q1 2022 and held it in 6 quarters. The position peaked at $7.66M in Q1 2023. 256 funds tracked by Wall St. Rank hold APLS as of Q3 2023.

  • Brookfield Corp reported no remaining Apellis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Brookfield Corp sold 61,414 Apellis Pharmaceuticals shares in Q3 2023, an estimated $5.59M.
  • Brookfield Corp first reported a position in Apellis Pharmaceuticals in Q1 2022 and held it in 6 quarters.
  • Brookfield Corp's Apellis Pharmaceuticals position peaked at $7.66M in Q1 2023.
  • 256 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2023.

Based on Brookfield Corp's 13F filing for Q3 2023, filed 14 Nov 2023.